414 related articles for article (PubMed ID: 15352149)
1. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
Lasser R; Bossie CA; Gharabawi G; Eerdekens M; Nasrallah HA
J Affect Disord; 2004 Dec; 83(2-3):263-75. PubMed ID: 15555724
[TBL] [Abstract][Full Text] [Related]
4. Long-acting risperidone in stable patients with schizoaffective disorder.
Mohl A; Westlye K; Opjordsmoen S; Lex A; Schreiner A; Benoit M; Bräunig P; Medori R
J Psychopharmacol; 2005 Sep; 19(5 Suppl):22-31. PubMed ID: 16144783
[TBL] [Abstract][Full Text] [Related]
5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
6. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
7. Long-acting risperidone improves negative symptoms in stable psychotic patients.
Curtis VA; Katsafouros K; Möller HJ; Medori R; Sacchetti E
J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
Schmauss M; Sacchetti E; Kahn JP; Medori R
Int Clin Psychopharmacol; 2007 Mar; 22(2):85-92. PubMed ID: 17293708
[TBL] [Abstract][Full Text] [Related]
9. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
[TBL] [Abstract][Full Text] [Related]
10. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
11. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
12. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.
Lindenmayer JP; Khan A; Eerdekens M; Van Hove I; Kushner S
Eur Neuropsychopharmacol; 2007 Jan; 17(2):138-44. PubMed ID: 17049818
[TBL] [Abstract][Full Text] [Related]
14. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.
Kissling W; Glue P; Medori R; Simpson S
Hum Psychopharmacol; 2007 Dec; 22(8):505-13. PubMed ID: 17902187
[TBL] [Abstract][Full Text] [Related]
16. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.
Macfadden W; Bossie CA; Turkoz I; Haskins JT
Int Clin Psychopharmacol; 2010 Mar; 25(2):75-82. PubMed ID: 20101185
[TBL] [Abstract][Full Text] [Related]
17. Patient-based and clinician-based support for the remission criteria in schizophrenia.
Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
Chue P; Eerdekens M; Augustyns I; Lachaux B; Molcan P; Eriksson L; Pretorius H; David AS
Eur Neuropsychopharmacol; 2005 Jan; 15(1):111-7. PubMed ID: 15572280
[TBL] [Abstract][Full Text] [Related]
19. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study.
Vieta E; Goikolea JM; Corbella B; Benabarre A; Reinares M; Martínez G; Fernández A; Colom F; Martínez-Arán A; Torrent C;
J Clin Psychiatry; 2001 Oct; 62(10):818-25. PubMed ID: 11816872
[TBL] [Abstract][Full Text] [Related]
20. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
